Search Within

David Hyman

  1. "Gynecology Disease Management Team "
Formats
  1. Journal Article (46)
  2. Meeting Abstract (25)
  3. Book Section (1)
Groups
  1. Department of Medicine (72)
  2. Early Drug Development Service (72)
  3. Gynecology Disease Management Team (72)
  4. Solid Tumor Oncology Division (72)
  5. Gynecologic Medicine Service (62)
  6. GDMT, Medicine (61)

More Groups

People
  1. Carol Aghajanian (32)
  2. Rachel Grisham (29)
  3. Vicky Makker (22)
  4. Alexia Iasonos (21)
  5. David Solit (18)
  6. Martee Hensley (18)

More People

Years
  1. 2021 (1)
  2. 2020 (10)
  3. 2019 (7)
  4. 2018 (11)
  5. 2017 (10)
  6. 2016 (3)

More Years

Publications
  1. Journal of Clinical Oncology (16)
  2. Gynecologic Oncology (9)
  3. Clinical Cancer Research (7)
  4. International Journal of Gynecological Cancer (4)
  5. Annals of Oncology (3)
  6. Cancer (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (19)
  2. American Association for Cancer Research (12)
  3. Elsevier B.V. (10)
  4. Lippincott Williams & Wilkins (7)
  5. Springer (4)
  6. Elsevier Inc. (3)

More Publishers

Results (72)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II trial of enzalutamide in patients with androgen receptor positive (AR+) ovarian, primary peritoneal or fallopian tube cancer and one, two, or three prior therapies
    Meeting Abstract

    Grisham, R. N.; Giri, D. D.; Iasonos, A.; Zhou, Q.; Girshman, J.; McGrath, S. P.; O'Cearbhaill, R. E.; Sabbatini, P.; Tew, W. P.; Hyman, D. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Somatic mutations in homologous recombination pathway genes in ovarian cancer
    Meeting Abstract

    Aghajanian, C.; DeLair, D.; Grisham, R. N.; Hensley, M. L.; Konner, J. A.; Makker, V.; O'Cearbhaill, R. E.; Sabbatini, P.; Soumerai, T.; Charen, A. S.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
    Journal Article

    Smyth, L. M.; Monson, K. R.; Jhaveri, K.; Drilon, A.; Li, B. T.; Abida, W.; Iyer, G.; Gerecitano, J. F.; Gounder, M.; Harding, J. J.; more...
    Investigational New Drugs (2017)

    Fulltext@MSK | Save
  • Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer
    Journal Article

    Weigelt, B.; Comino-MeĢndez, I.; de Bruijn, I.; Tian, L.; Meisel, J. L.; Garcia-Murillas, I.; Fribbens, C.; Cutts, R.; Martelotto, L. G.; Ng, C. K. Y.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma
    Journal Article

    Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Straus, D. J.; Moskowitz, A. J.; Younes, A.; Matasar, M. J.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
    Journal Article

    Zehir, A.; Benayed, R.; Shah, R. H.; Syed, A.; Middha, S.; Kim, H. R.; Srinivasan, P.; Gao, J.; Chakravarty, D.; Devlin, S. M.; more...
    Nature Medicine (2017)

    Fulltext@MSK | Save
  • Niraparib in recurrent ovarian cancer
    Journal Article

    Schram, A. M.; Aghajanian, C. A.; Hyman, D. M.
    New England Journal of Medicine (2017)

    Fulltext@MSK | Save
  • Next-generation assessment of human growth factor receptor 2 (ERBB2) amplification status: Clinical validation in the context of a hybrid capture-based, comprehensive solid tumor genomic profiling assay
    Journal Article

    Ross, D. S.; Zehir, A.; Cheng, D. T.; Benayed, R.; Nafa, K.; Hechtman, J. F.; Janjigian, Y. Y.; Weigelt, B.; Razavi, P.; Hyman, D. M.; more...
    Journal of Molecular Diagnostics (2017)

    Fulltext@MSK | Save
  • A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D
    Journal Article

    Hyman, D. M.; Sill, M. W.; Lankes, H. A.; Piekarz, R.; Shahin, M. S.; Ridgway, M. R.; Backes, F.; Tenney, M. E.; Mathews, C. A.; Hoffman, J. S.; more...
    Gynecologic Oncology (2017)

    Fulltext@MSK | Save
  • Lurbinectedin (PM01183) plus paclitaxel (P), recommended dose (RD) expansion results with or without the addition of bevacizumab (Bev) in patients (pts) with selected solid tumors
    Meeting Abstract

    Drilon, A.; Garralda, E.; Stathis, A.; Szyldergemajn, S.; Hyman, D.; Boni, V.; Griguolo, G.; Martinez, E. J.; Makker, V.; Canziani, L.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save